Last month

Novo Nordisk brought a new mechanism to ADA 2026 — and the numbers were hard to ignore

At the American Diabetes Association's 2026 Scientific Sessions in New Orleans last month, Novo Nordisk presented Phase 2b results for zenagamtide — the drug most of the biotech coverage still calls amycretin — that drew attention from people tracking the GLP-1 successor race. In a 36-week, randomized, double-blind, placebo-controlled trial in 262 adults with type 2 diabetes, the highest dose arm (40 mg subcutaneous, once weekly) achieved a mean 14.6% body weight reduction, versus 2.1% on placebo. A1C dropped 1.71 percentage points at the same dose, with 89.1% of participants reaching A1C below 7% and 76.2% reaching 6.5% or lower. Novo Nordisk specifically noted that no weight loss plateau had appeared by week 36 at the highest dose — a detail the company flagged because weight plateau behavior around that timeframe is a documented pattern in GLP-1 monotherapies. And the Phase 3 schedule is public: AMAZE 7, a direct head-to-head comparison of zenagamtide versus semaglutide in people with obesity, is confirmed to start in September 2026. [The ADA 2026 Phase 2b press release](https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html) is the primary source for the trial data.

The actual mechanism

a single molecule activating GLP-1 and amylin pathways — and that second receptor is the whole story

What separates amycretin from every other drug in the GLP-1 category is the second receptor it activates. Semaglutide hits GLP-1 receptors. Tirzepatide adds GIP. Retatrutide adds glucagon. Amycretin adds amylin receptors — and that is a biologically distinct pathway. GLP-1 receptor activation handles the incretin side: slowed gastric emptying, glucose-dependent insulin release, and appetite reduction through hypothalamic and brainstem circuits. Amylin is an endogenous pancreatic peptide hormone co-secreted with insulin after meals. Its satiety role runs through a different part of the brainstem — the area postrema and nucleus tractus solitarius, regions that process meal-size signals, distinct from the hypothalamic pathways GLP-1 primarily works through. Amylin also blunts post-meal glucagon release, adding a second mechanism on glucose regulation that does not duplicate what GLP-1 already does. Pramlintide, the first FDA-approved amylin analog in the United States, was always a separate injection from insulin — the amylin side alone produced real but modest results. The hypothesis behind combining both in a single molecule is that two complementary satiety systems produce more sustained appetite suppression than either alone. The ADA 2026 no-plateau finding is consistent with that hypothesis. It is Phase 2 data, not a Phase 3 efficacy endpoint.

The public framing

the 'next Ozempic' story arrived about a year before the Phase 3 head-to-head did

Online, amycretin is being discussed almost entirely through the GLP-1 succession frame: the drug that makes Ozempic look like last generation, the Novo Nordisk answer to Eli Lilly's retatrutide, the next milestone on the obesity-pharmacology timeline. That framing is not wrong — it is running about a year ahead of the clinical record. The AMAZE Phase 3 program covers obesity, type 2 diabetes, metabolic-associated steatohepatitis, and obstructive sleep apnea. AMAZE 1, the long-term obesity safety and efficacy trial, started enrolling in February 2026. AMAZE 7, the direct comparison against semaglutide in obesity, starts in September 2026. Novo Nordisk's chief scientific officer described zenagamtide as one of four pipeline assets the company expects to be competitive with retatrutide — that is an internal development framing from the company that owns the compound. It is not a comparison based on a trial that has run. People who encountered amycretin after the ADA conference are treating it as an alternative to current GLP-1 drugs they might use or wait for. That is a reasonable set of questions to want answered. They are not questions the current Phase 2 evidence base can settle.

What the data says

two controlled readouts with strong Phase 2 signal — and a Phase 3 program that hasn't read out yet

The evidence base for amycretin spans two trials in two different populations. The Phase 2a readout — the first human data — enrolled adults with overweight or obesity but without type 2 diabetes. The subcutaneous formulation showed up to 24.3% mean body weight loss against placebo; an oral version showed 13.1% over 12 weeks against placebo. Those numbers drew attention because they compared favorably to early Phase 2 data from semaglutide and tirzepatide. The Phase 2b data presented at ADA 2026 shifted the population to adults with type 2 diabetes — a clinically distinct question. In 262 participants over 36 weeks, the highest dose arm showed 14.6% weight loss and 1.71-percentage-point A1C reduction, with 89.1% reaching glycemic targets. Safety in both phases was dominated by GI adverse events consistent with the incretin class. No safety signals emerged outside that pattern. [PubMed literature on amycretin and zenagamtide](https://pubmed.ncbi.nlm.nih.gov/?term=amycretin) and [ClinicalTrials.gov records for the AMAZE program](https://clinicaltrials.gov/search?term=amycretin) document the accumulating evidence. What the evidence does not yet contain: a Phase 3 efficacy readout, a completed head-to-head against any approved GLP-1 therapy, or the large-scale safety database that precedes regulatory submission. All of that is in the AMAZE program. None of it has reported yet.

Early human — PeptideFactCheck stance

real Phase 2 signal, real Phase 3 uncertainty — and a head-to-head that's months away from starting

Amycretin holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. That tier is the accurate description of where the compound sits in July 2026. Two Phase 2 readouts across two populations both produced meaningful weight loss numbers against placebo. The no-plateau finding at 36 weeks is consistent with the dual-mechanism theory and represents a potential differentiator from GLP-1 monotherapy — if Phase 3 replicates it at scale. Novo Nordisk's internal pipeline framing places zenagamtide alongside retatrutide as a competitive asset. AMAZE 7, the semaglutide head-to-head in obesity, starts in September. Both are clinical development facts, not approval facts. [FDA guidance on unapproved GLP-1 and metabolic drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) applies to the broader investigational landscape amycretin sits within — investigational compounds marketed outside registered trials are a documented category of concern. The ADA 2026 readout produced a strong Phase 2 signal. The September trial start is the next calendar event. The completed Phase 3 data and any regulatory submission are the events that close the clinical case. None of them have happened yet, and the Early human tier will hold until one of them does.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.